Aspirin in the Prevention of Cardiovascular Events in Hemodialysis Patients

• Status: Withdrawn
• Trial end date: 2018-01-15
• Target enrollment: 0
• Participant gender: All

Summary

The study is prospectively initiated to: (1) evaluate the alterations in platelet function to aspirin therapy and the prevalence of aspirin resistance in patients with chronic kidney disease undergoing hemodialysis, and (2) compare the incidence of vascular events (myocardial infarction, cardiac death, stroke, vascular access thrombosis, or revascularization procedure) and the safety profile among placebo-treated, aspirin-resistant and aspirin-sensitive patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
• Collaborator: Taipei Veterans General Hospital, Taiwan
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• patients with end-stage renal disease who are undergoing long-term hemodialysis.

Exclusion Criteria:

Patients will be excluded if there is evidence of

• a recent history of acute uremia,

• previous adverse reaction to a aspirin or history of aspirin hypersensitivity (eg, aspirin-induced asthma or angioedema),

• concurrent treatment with other antiplatelet agent (clopidogrel or ticlopidine), steroidal drugs, or nonsteroidal anti-inflammatory drugs,

• high immediate risk for bleeding (eg, active peptic ulceration, recent injury, or hemophilia), or

• life-threatening condition other than end-stage renal disease or vascular disease (eg, non-skin cancer).